<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930952</url>
  </required_header>
  <id_info>
    <org_study_id>157-2018</org_study_id>
    <nct_id>NCT04930952</nct_id>
  </id_info>
  <brief_title>Complications of Ethanol-amine Oleate Intralesional Sclerotherapy</brief_title>
  <official_title>Complications of Ethanol-amine Oleate Intralesional Sclerotherapy Injections of Maxillofacial Venous Malformations in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suez Canal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suez Canal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to clarify complications of Ethanolamine Oleate intralesional&#xD;
      injections of maxillofacial venous formations in pediatric patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maxillofacial Venous malformations cause many functional and esthetic complications in&#xD;
      children, intralesional sclerotherapy is the best choice of treatment; and Ethanol-amine&#xD;
      Oleate has been the most commonly used sclerosing agent.&#xD;
&#xD;
      The aim of this study is to clarify complications of Ethanolamine Oleate intralesional&#xD;
      injections of maxillofacial venous formations&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Actual">March 3, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>12 months</time_frame>
    <description>Complete Response - Marked Improvement - Moderate Improvement - No Response</description>
  </primary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Venous Malformation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol-amine Oleate Sclerotherapy Injection</intervention_name>
    <description>Intralesional Sclerotherapy Injection</description>
    <other_name>Sclerotherapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients of age up to 12 years having maxillofacial venous malformations&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: maxillofacial venous malformation&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with lung, liver, or kidney diseases&#xD;
&#xD;
          2. Patients with Klippel-Trenaunay syndrome&#xD;
&#xD;
          3. Patients mental or physical disabilities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sarah Arafat, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Lecturer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Suez Canal University</name>
      <address>
        <city>Ismailia</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Suez Canal University</investigator_affiliation>
    <investigator_full_name>Sarah Arafat</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <keyword>Maxillofacial</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Venous Malformations</keyword>
  <keyword>Ethanol-amine Oleate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

